Back to top
more

Heron Therapeutics, Inc. (HRTX)

(Real Time Quote from BATS)

$17.61 USD

17.61
584,467

-0.09 (-0.51%)

Updated Oct 15, 2019 03:01 PM ET

Add to portfolio

3-Hold     3    

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1
2
3
4
5
S&P
Strong Buy
Buy
Hold
Sell
Strong Sell
500
24.50%
17.69%
9.28%
4.86%
1.63%
10.50%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

F Value | F Growth | B Momentum | F VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Zacks News

Zacks Equity Research

Heron Therapeutics (HRTX) Catches Eye: Stock Jumps 6.2%

Heron Therapeutics (HRTX) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

HRTX FGEN

Zacks Equity Research

Heron Therapeutics (HRTX) Reports Q2 Loss, Tops Revenue Estimates

Heron Therapeutics (HRTX) delivered earnings and revenue surprises of 7.35% and 18.11%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

HRTX

Zacks Equity Research

Heron Therapeutics (HRTX) Reports Q1 Loss, Tops Revenue Estimates

Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -70.21% and 15.34%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

HRTX

Zacks Equity Research

Heron Therapeutics (HRTX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Heron Therapeutics (HRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

HRTX

Zacks Equity Research

Implied Volatility Surging for Heron Therapeutics (HRTX) Stock Options

Investors need to pay close attention to Heron Therapeutics (HRTX) stock based on the movements in the options market lately.

HRTX

Zacks Equity Research

Heron Therapeutics (HRTX) Reports Q4 Loss, Tops Revenue Estimates

Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -36.96% and 2.83%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

HRTX

Zacks Equity Research

Company News For Jan 2, 2019

Companies In The News Are: BA,TXT,HRTX,GOOS,CWH

BA TXT CWH HRTX GOOS

Zacks Equity Research

Heron Gains on Priority Review Designation for Pain Drug

Heron (HRTX) soars after the FDA accepted the company's NDA for pain drug, HTX-011, and granted Priority Review designation to the application.

BMY ENDP HRTX MNK

Zacks Equity Research

Heron Therapeutics (HRTX) Reports Q3 Loss, Tops Revenue Estimates

Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -4.26% and 6.31%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

HRTX

Zacks Equity Research

Heron Therapeutics (HRTX) Q3 Earnings Preview: What to Expect

Heron Therapeutics (HRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

HRTX

Zacks Equity Research

Implied Volatility Surging for Heron Therapeutics (HRTX) Stock Options

Investors need to pay close attention to Heron Therapeutics (HRTX) stock based on the movements in the options market lately.

HRTX

Zacks Equity Research

Heron Therapeutics (HRTX) Reports Q2 Loss, Tops Revenue Estimates

Heron Therapeutics (HRTX) delivered earnings and revenue surprises of 21.74% and 23.30%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

HRTX

Zacks Equity Research

Heron's Pain Candidate Meets Endpoint in Pivotal Studies

Heron Therapeutics' (HRTX) pipeline candidate, HTX-011, meets primary endpoint in two pivotal phase III studies in bunionectomy and hernia repair.

LGND HZNP PCRX HRTX

Zacks Equity Research

Options Traders Expect Huge Moves in Heron Therapeutics (HRTX) Stock

Investors in Heron Therapeutics (HRTX) need to pay close attention to the stock based on moves in the options market lately.

HRTX

Zacks Equity Research

Should You Buy Heron Therapeutics (HRTX) Ahead of Earnings

Heron Therapeutics (HRTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP ahead of earnings.

HRTX